Serum 1,5-anhydroglucitol (Glycomark™) levels in children with and without type 1 diabetes mellitus

Thanh M. Nguyen, Luisa M. Rodriguez, Kimberly J. Mason, Rubina A. Heptulla

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Postprandial hyperglycemia associated with diabetes is a risk factor for cardiovascular disease. Currently, glycated hemoglobin A1c (HgbA1c) and glycated protein fructosamine are not sensitive markers for acute and short-term hyperglycemia. 1,5-Anhydroglucitol (1,5-AG) (Glycomark™; Tomen America, New York, NY, USA) is reported in adults with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) as a marker for postmeal hyperglycemia. However, the reference ranges for 1,5-AG in normal children and children with T1DM are not known. We studied 1,5-AG levels in 10 control children (6 males and 4 females) and 10 children with T1DM (7 males and 3 females). The levels of 1,5-AG in the normal controls were higher than those in children with T1DM (24.60 ± 3.99 μg/mL vs. 4.75 ± 2.95 μg/mL; p < 0.0001). There were no gender differences noted. The 1,5-AG levels were negatively correlated with HgbA 1c (r = -0.9366; p < 0.0001) and the peak postmeal plasma glucose concentrations (Pearson r = -7230; p = 0.0003). Our findings suggest that despite good glycemic control, postprandial glucose concentrations are elevated and that 1,5-AG showed a difference between controls and children with T1DM. The data are comparable with previous studies in normal adults and in those with T1DM and T2DM. They support the use of 1,5-AG concentrations, together with HgbA1c, to evaluate therapy, especially to target postprandial hyperglycemia.

Original languageEnglish (US)
Pages (from-to)214-219
Number of pages6
JournalPediatric Diabetes
Volume8
Issue number4
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Hyperglycemia
Serum
Type 2 Diabetes Mellitus
Fructosamine
Glucose
Glycosylated Hemoglobin A
1,5-anhydroglucitol
Reference Values
Hemoglobins
Cardiovascular Diseases
Proteins

Keywords

  • Adolescent
  • Glycemic control
  • HbA
  • Pediatric
  • Postprandial

ASJC Scopus subject areas

  • Internal Medicine
  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

Serum 1,5-anhydroglucitol (Glycomark™) levels in children with and without type 1 diabetes mellitus. / Nguyen, Thanh M.; Rodriguez, Luisa M.; Mason, Kimberly J.; Heptulla, Rubina A.

In: Pediatric Diabetes, Vol. 8, No. 4, 08.2007, p. 214-219.

Research output: Contribution to journalArticle

Nguyen, Thanh M. ; Rodriguez, Luisa M. ; Mason, Kimberly J. ; Heptulla, Rubina A. / Serum 1,5-anhydroglucitol (Glycomark™) levels in children with and without type 1 diabetes mellitus. In: Pediatric Diabetes. 2007 ; Vol. 8, No. 4. pp. 214-219.
@article{34993402deb94002a2f74ea7c4b6ed4a,
title = "Serum 1,5-anhydroglucitol (Glycomark™) levels in children with and without type 1 diabetes mellitus",
abstract = "Postprandial hyperglycemia associated with diabetes is a risk factor for cardiovascular disease. Currently, glycated hemoglobin A1c (HgbA1c) and glycated protein fructosamine are not sensitive markers for acute and short-term hyperglycemia. 1,5-Anhydroglucitol (1,5-AG) (Glycomark™; Tomen America, New York, NY, USA) is reported in adults with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) as a marker for postmeal hyperglycemia. However, the reference ranges for 1,5-AG in normal children and children with T1DM are not known. We studied 1,5-AG levels in 10 control children (6 males and 4 females) and 10 children with T1DM (7 males and 3 females). The levels of 1,5-AG in the normal controls were higher than those in children with T1DM (24.60 ± 3.99 μg/mL vs. 4.75 ± 2.95 μg/mL; p < 0.0001). There were no gender differences noted. The 1,5-AG levels were negatively correlated with HgbA 1c (r = -0.9366; p < 0.0001) and the peak postmeal plasma glucose concentrations (Pearson r = -7230; p = 0.0003). Our findings suggest that despite good glycemic control, postprandial glucose concentrations are elevated and that 1,5-AG showed a difference between controls and children with T1DM. The data are comparable with previous studies in normal adults and in those with T1DM and T2DM. They support the use of 1,5-AG concentrations, together with HgbA1c, to evaluate therapy, especially to target postprandial hyperglycemia.",
keywords = "Adolescent, Glycemic control, HbA, Pediatric, Postprandial",
author = "Nguyen, {Thanh M.} and Rodriguez, {Luisa M.} and Mason, {Kimberly J.} and Heptulla, {Rubina A.}",
year = "2007",
month = "8",
doi = "10.1111/j.1399-5448.2007.00228.x",
language = "English (US)",
volume = "8",
pages = "214--219",
journal = "Pediatric Diabetes",
issn = "1399-543X",
publisher = "Blackwell Munksgaard",
number = "4",

}

TY - JOUR

T1 - Serum 1,5-anhydroglucitol (Glycomark™) levels in children with and without type 1 diabetes mellitus

AU - Nguyen, Thanh M.

AU - Rodriguez, Luisa M.

AU - Mason, Kimberly J.

AU - Heptulla, Rubina A.

PY - 2007/8

Y1 - 2007/8

N2 - Postprandial hyperglycemia associated with diabetes is a risk factor for cardiovascular disease. Currently, glycated hemoglobin A1c (HgbA1c) and glycated protein fructosamine are not sensitive markers for acute and short-term hyperglycemia. 1,5-Anhydroglucitol (1,5-AG) (Glycomark™; Tomen America, New York, NY, USA) is reported in adults with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) as a marker for postmeal hyperglycemia. However, the reference ranges for 1,5-AG in normal children and children with T1DM are not known. We studied 1,5-AG levels in 10 control children (6 males and 4 females) and 10 children with T1DM (7 males and 3 females). The levels of 1,5-AG in the normal controls were higher than those in children with T1DM (24.60 ± 3.99 μg/mL vs. 4.75 ± 2.95 μg/mL; p < 0.0001). There were no gender differences noted. The 1,5-AG levels were negatively correlated with HgbA 1c (r = -0.9366; p < 0.0001) and the peak postmeal plasma glucose concentrations (Pearson r = -7230; p = 0.0003). Our findings suggest that despite good glycemic control, postprandial glucose concentrations are elevated and that 1,5-AG showed a difference between controls and children with T1DM. The data are comparable with previous studies in normal adults and in those with T1DM and T2DM. They support the use of 1,5-AG concentrations, together with HgbA1c, to evaluate therapy, especially to target postprandial hyperglycemia.

AB - Postprandial hyperglycemia associated with diabetes is a risk factor for cardiovascular disease. Currently, glycated hemoglobin A1c (HgbA1c) and glycated protein fructosamine are not sensitive markers for acute and short-term hyperglycemia. 1,5-Anhydroglucitol (1,5-AG) (Glycomark™; Tomen America, New York, NY, USA) is reported in adults with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) as a marker for postmeal hyperglycemia. However, the reference ranges for 1,5-AG in normal children and children with T1DM are not known. We studied 1,5-AG levels in 10 control children (6 males and 4 females) and 10 children with T1DM (7 males and 3 females). The levels of 1,5-AG in the normal controls were higher than those in children with T1DM (24.60 ± 3.99 μg/mL vs. 4.75 ± 2.95 μg/mL; p < 0.0001). There were no gender differences noted. The 1,5-AG levels were negatively correlated with HgbA 1c (r = -0.9366; p < 0.0001) and the peak postmeal plasma glucose concentrations (Pearson r = -7230; p = 0.0003). Our findings suggest that despite good glycemic control, postprandial glucose concentrations are elevated and that 1,5-AG showed a difference between controls and children with T1DM. The data are comparable with previous studies in normal adults and in those with T1DM and T2DM. They support the use of 1,5-AG concentrations, together with HgbA1c, to evaluate therapy, especially to target postprandial hyperglycemia.

KW - Adolescent

KW - Glycemic control

KW - HbA

KW - Pediatric

KW - Postprandial

UR - http://www.scopus.com/inward/record.url?scp=34547112833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547112833&partnerID=8YFLogxK

U2 - 10.1111/j.1399-5448.2007.00228.x

DO - 10.1111/j.1399-5448.2007.00228.x

M3 - Article

VL - 8

SP - 214

EP - 219

JO - Pediatric Diabetes

JF - Pediatric Diabetes

SN - 1399-543X

IS - 4

ER -